Telehealth & Digital Health

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

Treating over 100,000 patients in two years, a novel gel therapy is leading a paradigm shift in interventional dry eye management. Here's how.

With its lead drug in Phase 3 and a strong Biogen partnership, Stoke Therapeutics prepares to update investors on its disease-modifying Dravet syndrome therapy.

A new clinical trial is underway for a next-gen aortic valve, promising a less invasive procedure and improved durability for millions of patients.

The eyecare tech leader will demo its redesigned EHR at ASCRS 2026, promising streamlined workflows. But can it stand out in a competitive market?

With its future riding on a pivotal trial for avexitide, Amylyx's upcoming conference presentation offers a crucial look into its post-ALS strategy.

A new VC-backed program is giving elite female athletes the tailored health tools sports science has long ignored, aiming to optimize performance and longevity.

SharkNinja's new air purifier uses proactive sensors and a 6-year filter, challenging the market by tackling pollutants before they rise.

Blue Faery recognizes two doctors whose groundbreaking research in immunotherapy and targeted drugs has created new standards of care for liver cancer patients.

FDA approves a pivotal trial for a novel heart valve, potentially revolutionizing treatment for millions with severe tricuspid regurgitation.

Ontario and Quebec expand public coverage for a potent cholesterol drug, offering a critical lifeline to thousands at risk of a second cardiovascular event.

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

This April, families nationwide are walking to fund a new strategy for Lennox-Gastaut Syndrome, aiming to slash diagnosis times and find real cures.

Biopharma firm GENFIT sees soaring Iqirvo sales and a cash runway past 2028, overshadowing a net loss driven by strategic, non-cash write-downs.

A new partnership brings FDA-cleared eye-tracking tech to more providers, promising to cut year-long waits for autism diagnosis to mere minutes.

A Canadian company has earned top marks from healthcare professionals for its clinically proven approach to preventing UTIs. Here’s what sets Utiva apart.

After a period of limited availability, the Ellipsys Vascular Access System is set for a 2026 relaunch, promising a less invasive option for dialysis patients.

Lipocine's stock plummets after its PPD drug fails a Phase 3 trial, but a promising signal in a patient subset offers a narrow path forward.

New platform combines genetic, epigenetic, and lab tests with AI and coaching, aiming to simplify personal health in a crowded and cautious market.